Midazolam is a widely used central nervous system depressant. It is used for the treatment of insomnia, seizure, and induction of sedation or amnesia for operations. It is metabolized by cytochrome CYP3A and is a widely used probing drug for the evaluation of CYP3A activity in drug-to-drug interaction (DDI) studies. In this study, we develop a method to quantify midazolam in human plasma.

Antisense oligonucleotides (ASOs) are short, chemically modified, single-stranded DNA/RNA oligonucleotides that specifically target genes of interest and regulate target protein biosynthesis. In this study, we quantify antisense oligonucleotides in plasma using MSD.

Antibody-drug conjugates (ADCs) have become promising therapy for the treatment of cancers. Among all the ADCs under development, 2/3 of them are interchain cysteine-linked ADCs. The ADCs are manufactured by partially reducing the 4 pairs of interchain disulfide bonds followed by conjugate cytotoxic payloads to the thiols, as a consequence, the antibodies are linked with 0, 2, 4, 6, 8 drugs. The drug-to-antibody ratio (DAR) and the drug linking position are important parameters that affect the therapeutic effects and need to be well characterized. In this study, we successfully characterize a method for the interchain cysteine linked ADC in a biological matrix.